$SNTA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in MADRIGAL PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in MADRIGAL PHARMACEUTICALS, INC.. Get notifications about new insider transactions in MADRIGAL PHARMACEUTICALS, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 20 2013 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 4.00 | 200,000 | 799,160 | 2,200,000 | 2 M to 2.2 M (+10.00 %) |
| Jun 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Buy | P | 4.12 | 20,000 | 82,374 | 2,023,135 | 2 M to 2 M (+1.00 %) |
| Jun 17 2013 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Buy | P | 4.06 | 10,000 | 40,550 | 2,003,135 | 2 M to 2 M (+0.50 %) |
| Jun 06 2013 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Buy | P | 4.04 | 10,000 | 40,390 | 1,993,135 | 2 M to 2 M (+0.50 %) |
| Jun 06 2013 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 4.31 | 738,900 | 3,186,950 | 2,000,000 | 1.3 M to 2 M (+58.59 %) |
| Jun 06 2013 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 4.71 | 756,000 | 3,561,743 | 1,261,100 | 505.1 K to 1.3 M (+149.67 %) |
| Jun 06 2013 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 4.99 | 505,100 | 2,521,661 | 505,100 | 0 to 505.1 K |
| Jun 06 2013 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Buy | P | 4.58 | 10,000 | 45,800 | 35,249 | 25.2 K to 35.2 K (+39.61 %) |
| Jun 06 2013 | SNTA | SYNTA PHARMACEUTIC ... | WILSON ROBERT N | Director | Buy | P | 5.00 | 10,000 | 50,000 | 699,679 | 689.7 K to 699.7 K (+1.45 %) |
| Mar 13 2013 | SNTA | SYNTA PHARMACEUTIC ... | Ramachandra Sumant | President, R&D | Option Exercise | A | 9.59 | 225,000 | 2,157,750 | 225,000 | |
| Mar 13 2013 | SNTA | SYNTA PHARMACEUTIC ... | Ramachandra Sumant | President, R&D | Grant | A | 0.00 | 75,000 | 8 | 75,000 | 0 to 75 K |
| Mar 07 2013 | SNTA | SYNTA PHARMACEUTIC ... | Ehrlich Keith S | VP, Fin. and Admin. ... | Option Exercise | A | 9.65 | 52,525 | 506,866 | 52,525 | |
| Mar 07 2013 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Option Exercise | A | 9.65 | 52,143 | 503,180 | 52,143 | |
| Mar 07 2013 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Option Exercise | A | 9.65 | 100,000 | 965,000 | 100,000 | |
| Mar 07 2013 | SNTA | SYNTA PHARMACEUTIC ... | Singh Amar | Sr. VP, Chief Busin ... | Option Exercise | A | 9.65 | 73,505 | 709,323 | 73,505 | |
| Mar 07 2013 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Option Exercise | A | 9.65 | 230,000 | 2,219,500 | 230,000 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 5.47 | 2,250 | 12,308 | 2,250 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 5.47 | 5,000 | 27,350 | 5,000 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 5.09 | 2,500 | 12,725 | 0 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 5.09 | 5,500 | 27,995 | 0 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 2.59 | 2,500 | 6,475 | 0 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 2.59 | 5,500 | 14,245 | 0 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 2.38 | 2,500 | 5,950 | 0 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 2.38 | 5,500 | 13,090 | 0 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 7.03 | 2,500 | 17,575 | 0 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 7.03 | 5,500 | 38,665 | 0 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | M | 10.84 | 75,000 | 813,225 | 0 | |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 5.47 | 2,250 | 12,308 | 316,255 | 314 K to 316.3 K (+0.72 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 5.47 | 5,000 | 27,350 | 314,005 | 309 K to 314 K (+1.62 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 5.09 | 2,500 | 12,725 | 309,005 | 306.5 K to 309 K (+0.82 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 5.09 | 5,500 | 27,995 | 306,505 | 301 K to 306.5 K (+1.83 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 2.59 | 2,500 | 6,475 | 301,005 | 298.5 K to 301 K (+0.84 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 2.59 | 5,500 | 14,245 | 298,505 | 293 K to 298.5 K (+1.88 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 2.38 | 2,500 | 5,950 | 293,005 | 290.5 K to 293 K (+0.86 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 2.38 | 5,500 | 13,090 | 290,505 | 285 K to 290.5 K (+1.93 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 7.03 | 2,500 | 17,575 | 285,005 | 282.5 K to 285 K (+0.88 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 7.03 | 5,500 | 38,665 | 282,505 | 277 K to 282.5 K (+1.99 %) |
| Jan 24 2013 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | M | 10.84 | 75,000 | 813,225 | 277,005 | 202 K to 277 K (+37.13 %) |
| Dec 14 2012 | SNTA | SYNTA PHARMACEUTIC ... | WILSON ROBERT N | Director | Grant | A | 8.60 | 58,140 | 500,004 | 689,679 | 631.5 K to 689.7 K (+9.21 %) |
| Dec 14 2012 | SNTA | SYNTA PHARMACEUTIC ... | KUFE DONALD W | Director | Grant | A | 8.60 | 5,814 | 50,000 | 17,748 | 11.9 K to 17.7 K (+48.72 %) |
| Dec 14 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Grant | A | 8.60 | 2,325,581 | 19,999,997 | 3,273,281 | 947.7 K to 3.3 M (+245.39 %) |
| Dec 14 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 8.60 | 175,000 | 1,505,000 | 175,000 | 0 to 175 K |
| Dec 14 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 8.60 | 75,000 | 645,000 | 2,673,383 | 2.6 M to 2.7 M (+2.89 %) |
| Dec 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | Singh Amar | Sr. VP, Chief Busin ... | Payment of Exercise | F | 8.21 | 3,969 | 32,585 | 21,031 | 25 K to 21 K (-15.88 %) |
| Dec 14 2012 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Grant | A | 8.60 | 10,000 | 86,000 | 2,383,135 | 2.4 M to 2.4 M (+0.42 %) |
| Nov 14 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 6.95 | 10,500 | 73,009 | 947,700 | 937.2 K to 947.7 K (+1.12 %) |
| Nov 14 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 6.89 | 27,200 | 187,449 | 937,200 | 910 K to 937.2 K (+2.99 %) |
| Nov 13 2012 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Buy | P | 7.12 | 10,000 | 71,200 | 2,373,135 | 2.4 M to 2.4 M (+0.42 %) |
| Sep 17 2012 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Option Exercise | A | 8.05 | 15,000 | 120,750 | 15,000 | |
| Sep 17 2012 | SNTA | SYNTA PHARMACEUTIC ... | Ehrlich Keith S | VP, Fin. and Admin. ... | Option Exercise | A | 8.05 | 15,000 | 120,750 | 15,000 | |
| Sep 17 2012 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Option Exercise | A | 8.05 | 25,000 | 201,250 | 25,000 | |
| Sep 17 2012 | SNTA | SYNTA PHARMACEUTIC ... | Singh Amar | Sr. VP, Chief Busin ... | Option Exercise | A | 8.05 | 25,000 | 201,250 | 25,000 | |
| Sep 17 2012 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Option Exercise | A | 8.05 | 100,000 | 805,000 | 100,000 | |
| Jul 27 2012 | SNTA | SYNTA PHARMACEUTIC ... | KUFE DONALD W | Director | Grant | A | 6.49 | 4,622 | 29,997 | 11,934 | 7.3 K to 11.9 K (+63.21 %) |
| Jul 27 2012 | SNTA | SYNTA PHARMACEUTIC ... | WILSON ROBERT N | Director | Grant | A | 6.49 | 100,000 | 649,000 | 631,539 | 531.5 K to 631.5 K (+18.81 %) |
| Jul 27 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Grant | A | 6.49 | 3,081,664 | 19,999,999 | 8,006,852 | 4.9 M to 8 M (+62.57 %) |
| Jul 27 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 6.49 | 770,416 | 5,000,000 | 2,598,383 | 1.8 M to 2.6 M (+42.15 %) |
| Jul 27 2012 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Grant | A | 6.49 | 20,000 | 129,800 | 2,363,135 | 2.3 M to 2.4 M (+0.85 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | KUFE DONALD W | Director | Option Exercise | A | 5.47 | 10,000 | 54,700 | 10,000 | |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | KUFE DONALD W | Director | Grant | A | 0.00 | 7,312 | 0 | 7,312 | 0 to 7.3 K |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | WILSON ROBERT N | Director | Option Exercise | A | 5.47 | 10,000 | 54,700 | 10,000 | |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | WILSON ROBERT N | Director | Grant | A | 0.00 | 914 | 0 | 531,539 | 530.6 K to 531.5 K (+0.17 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | WILSON ROBERT N | Director | Grant | A | 0.00 | 914 | 0 | 530,625 | 529.7 K to 530.6 K (+0.17 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | WILSON ROBERT N | Director | Grant | A | 0.00 | 7,312 | 0 | 529,711 | 522.4 K to 529.7 K (+1.40 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | REARDON WILLIAM S | Director | Option Exercise | A | 5.47 | 10,000 | 54,700 | 10,000 | |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | REARDON WILLIAM S | Director | Grant | A | 0.00 | 1,371 | 0 | 19,228 | 17.9 K to 19.2 K (+7.68 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | REARDON WILLIAM S | Director | Grant | A | 0.00 | 3,656 | 0 | 17,857 | 14.2 K to 17.9 K (+25.74 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | A | 5.47 | 4,500 | 24,615 | 4,500 | |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | A | 5.47 | 10,000 | 54,700 | 10,000 | |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 0.00 | 914 | 0 | 202,005 | 201.1 K to 202 K (+0.45 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 0.00 | 914 | 0 | 201,091 | 200.2 K to 201.1 K (+0.46 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 0.00 | 1,828 | 0 | 200,177 | 198.3 K to 200.2 K (+0.92 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 0.00 | 3,656 | 0 | 198,349 | 194.7 K to 198.3 K (+1.88 %) |
| Jul 03 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 0.00 | 7,312 | 0 | 194,693 | 187.4 K to 194.7 K (+3.90 %) |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Option Exercise | A | 5.47 | 10,000 | 54,700 | 10,000 | |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Grant | A | 0.00 | 914 | 0 | 4,925,188 | 4.9 M to 4.9 M (+0.02 %) |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Grant | A | 0.00 | 914 | 0 | 4,924,274 | 4.9 M to 4.9 M (+0.02 %) |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Grant | A | 0.00 | 7,312 | 0 | 4,923,360 | 4.9 M to 4.9 M (+0.15 %) |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 475,000 | 0 | 475,000 | 0 to 475 K |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 475,000 | 0 | 475,000 | 0 to 475 K |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 475,000 | 0 | 475,000 | 0 to 475 K |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 475,000 | 0 | 475,000 | 0 to 475 K |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 1,900,000 | 0 | 4,916,048 | 6.8 M to 4.9 M (-27.88 %) |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 5.45 | 910,000 | 4,959,318 | 6,816,048 | 5.9 M to 6.8 M (+15.41 %) |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | P | 5.35 | 150,000 | 801,900 | 1,827,967 | 1.7 M to 1.8 M (+8.94 %) |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Buy | P | 5.59 | 3,000 | 16,755 | 25,249 | 22.2 K to 25.2 K (+13.48 %) |
| Jul 02 2012 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Buy | P | 5.34 | 10,000 | 53,370 | 2,343,135 | 2.3 M to 2.3 M (+0.43 %) |
| Jun 20 2012 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Option Exercise | M | 2.49 | 7,170 | 17,853 | 16,530 | |
| Jun 20 2012 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Sell | S | 6.00 | 7,170 | 43,020 | 19,823 | 27 K to 19.8 K (-26.56 %) |
| Jun 20 2012 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Buy | M | 2.49 | 7,170 | 17,853 | 26,993 | 19.8 K to 27 K (+36.17 %) |
| Jun 06 2012 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Option Exercise | M | 2.49 | 7,170 | 17,853 | 23,700 | |
| Jun 06 2012 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Sell | S | 5.50 | 7,170 | 39,435 | 19,823 | 27 K to 19.8 K (-26.56 %) |
| Jun 06 2012 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Buy | M | 2.49 | 7,170 | 17,853 | 26,993 | 19.8 K to 27 K (+36.17 %) |
| Mar 08 2012 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Option Exercise | A | 4.22 | 185,000 | 780,700 | 185,000 | |
| Mar 08 2012 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Option Exercise | A | 4.22 | 48,760 | 205,767 | 48,760 | |
| Mar 08 2012 | SNTA | SYNTA PHARMACEUTIC ... | Singh Amar | Sr. VP, Business & ... | Option Exercise | A | 4.22 | 61,200 | 258,264 | 61,200 | |
| Mar 08 2012 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Option Exercise | A | 4.22 | 70,380 | 297,004 | 70,380 | |
| Mar 08 2012 | SNTA | SYNTA PHARMACEUTIC ... | Ehrlich Keith S | VP, Fin. and Admin. ... | Option Exercise | A | 4.22 | 48,760 | 205,767 | 48,760 | |
| Mar 08 2012 | SNTA | SYNTA PHARMACEUTIC ... | Koya Keizo | Sr. VP, Drug Develo ... | Option Exercise | A | 4.22 | 63,036 | 266,012 | 63,036 | |
| Mar 05 2012 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Sell | S | 4.70 | 2,555 | 12,006 | 22,249 | 24.8 K to 22.2 K (-10.30 %) |
| Mar 05 2012 | SNTA | SYNTA PHARMACEUTIC ... | Koya Keizo | Sr. VP, Drug Develo ... | Sell | S | 4.70 | 6,844 | 32,187 | 12,999 | 19.8 K to 13 K (-34.49 %) |
| Mar 05 2012 | SNTA | SYNTA PHARMACEUTIC ... | Ehrlich Keith S | VP, Fin. and Admin. ... | Sell | S | 4.70 | 4,397 | 20,662 | 17,573 | 22 K to 17.6 K (-20.01 %) |
| Jan 10 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 4.40 | 1,136,363 | 4,999,997 | 5,906,048 | 4.8 M to 5.9 M (+23.82 %) |
| Jan 10 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Jan 10 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Jan 10 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Jan 10 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Jan 10 2012 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Gift | G | 0.00 | 500,000 | 0 | 4,769,685 | 5.3 M to 4.8 M (-9.49 %) |
| Dec 09 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.95 | 11,059 | 43,727 | 5,269,685 | 5.3 M to 5.3 M (+0.21 %) |
| Dec 01 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.96 | 8,844 | 35,024 | 5,258,626 | 5.2 M to 5.3 M (+0.17 %) |
| Nov 29 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.94 | 25,016 | 98,473 | 5,249,782 | 5.2 M to 5.2 M (+0.48 %) |
| Nov 25 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.98 | 7,547 | 30,039 | 5,224,766 | 5.2 M to 5.2 M (+0.14 %) |
| Nov 25 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.96 | 453 | 1,793 | 5,217,219 | 5.2 M to 5.2 M (+0.01 %) |
| Nov 22 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.84 | 33,640 | 129,299 | 5,216,766 | 5.2 M to 5.2 M (+0.65 %) |
| Nov 22 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.71 | 21,000 | 77,921 | 5,183,126 | 5.2 M to 5.2 M (+0.41 %) |
| Sep 13 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.82 | 43,085 | 164,455 | 5,162,126 | 5.1 M to 5.2 M (+0.84 %) |
| Sep 13 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.77 | 110,149 | 415,702 | 5,119,041 | 5 M to 5.1 M (+2.20 %) |
| Sep 07 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.79 | 50,400 | 191,258 | 5,008,892 | 5 M to 5 M (+1.02 %) |
| Sep 07 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.89 | 46,057 | 179,245 | 4,958,492 | 4.9 M to 5 M (+0.94 %) |
| Sep 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Buy | P | 4.00 | 2,188 | 8,752 | 24,804 | 22.6 K to 24.8 K (+9.67 %) |
| Sep 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Buy | P | 4.07 | 312 | 1,270 | 22,616 | 22.3 K to 22.6 K (+1.40 %) |
| Aug 30 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.85 | 100 | 385 | 4,912,435 | 4.9 M to 4.9 M (0.00 %) |
| Aug 22 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.79 | 3,303 | 12,510 | 4,896,569 | 4.9 M to 4.9 M (+0.07 %) |
| Aug 24 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.72 | 5,167 | 19,225 | 4,912,335 | 4.9 M to 4.9 M (+0.11 %) |
| Aug 24 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.77 | 10,597 | 39,963 | 4,907,168 | 4.9 M to 4.9 M (+0.22 %) |
| Aug 10 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.70 | 33,978 | 125,593 | 4,893,266 | 4.9 M to 4.9 M (+0.70 %) |
| Aug 10 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.71 | 52,464 | 194,636 | 4,859,288 | 4.8 M to 4.9 M (+1.09 %) |
| Aug 10 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 3.77 | 41,700 | 157,347 | 4,806,824 | 4.8 M to 4.8 M (+0.88 %) |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | REARDON WILLIAM S | Director | Option Exercise | A | 5.09 | 5,500 | 27,995 | 5,500 | |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | REARDON WILLIAM S | Director | Grant | A | 0.00 | 1,964 | 0 | 14,201 | 12.2 K to 14.2 K (+16.05 %) |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | KUFE DONALD W | Director | Option Exercise | A | 5.09 | 5,500 | 27,995 | 5,500 | |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | WILSON ROBERT N | Director | Option Exercise | A | 5.09 | 5,500 | 27,995 | 5,500 | |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | A | 5.09 | 2,500 | 12,725 | 2,500 | |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Option Exercise | A | 5.09 | 5,500 | 27,995 | 5,500 | |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 0.00 | 3,929 | 0 | 187,381 | 183.5 K to 187.4 K (+2.14 %) |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Grant | A | 0.00 | 3,929 | 0 | 183,452 | 179.5 K to 183.5 K (+2.19 %) |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Option Exercise | A | 5.09 | 5,500 | 27,995 | 5,500 | |
| Jul 06 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Grant | A | 0.00 | 7,858 | 0 | 4,765,124 | 4.8 M to 4.8 M (+0.17 %) |
| Apr 26 2011 | SNTA | SYNTA PHARMACEUTIC ... | Koya Keizo | Sr. VP, Drug Develo ... | Sell | S | 6.00 | 10,000 | 60,000 | 19,843 | 29.8 K to 19.8 K (-33.51 %) |
| Apr 26 2011 | SNTA | SYNTA PHARMACEUTIC ... | Koya Keizo | Sr. VP, Drug Develo ... | Sell | S | 5.60 | 10,000 | 56,000 | 29,843 | 39.8 K to 29.8 K (-25.10 %) |
| Apr 18 2011 | SNTA | SYNTA PHARMACEUTIC ... | WILSON ROBERT N | Director | Buy | P | 4.89 | 50,000 | 244,500 | 522,399 | 472.4 K to 522.4 K (+10.58 %) |
| Apr 18 2011 | SNTA | SYNTA PHARMACEUTIC ... | Gollust Keith R | Director | Buy | P | 4.89 | 100,000 | 489,000 | 1,677,967 | 1.6 M to 1.7 M (+6.34 %) |
| Apr 18 2011 | SNTA | SYNTA PHARMACEUTIC ... | Kovner Bruce | Director | Buy | P | 4.89 | 1,431,493 | 7,000,001 | 4,757,266 | 3.3 M to 4.8 M (+43.04 %) |
| Mar 15 2011 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Buy | P | 4.45 | 5,000 | 22,250 | 2,333,135 | 2.3 M to 2.3 M (+0.21 %) |
| Mar 03 2011 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Option Exercise | A | 5.26 | 200,000 | 1,052,000 | 200,000 | |
| Mar 03 2011 | SNTA | SYNTA PHARMACEUTIC ... | Bahcall Safi R | President and CEO | Grant | A | 0.00 | 11,549 | 0 | 2,328,135 | 2.3 M to 2.3 M (+0.50 %) |
| Mar 03 2011 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Option Exercise | A | 5.26 | 100,000 | 526,000 | 100,000 | |
| Mar 03 2011 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Grant | A | 0.00 | 7,300 | 0 | 22,304 | 15 K to 22.3 K (+48.65 %) |
| Mar 03 2011 | SNTA | SYNTA PHARMACEUTIC ... | Vukovic Vojo | SVP, Chief Medical ... | Sell | S | 5.32 | 2,617 | 13,928 | 15,004 | 17.6 K to 15 K (-14.85 %) |
| Mar 03 2011 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | VP, IP and Legal, G ... | Option Exercise | A | 5.26 | 41,891 | 220,347 | 41,891 |